Merus N.V.
Merus N.V. (MRUS): 511 pipeline candidates · ~23 mo cash runway · 239 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
22.6 months
D/E 0.17 · 0% dilution
Lead: Phase 3
511 candidates
N/A
7 buys · 0 sells (180d)
A transparent, data-derived signal for Merus N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$6.8B
Cash
$368.2M
Quarterly Burn
$84.9M
Runway
22.6 mo
Revenue
$12.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (511 candidates)
| Drug | Phase |
|---|---|
| 19-28z/IL-18 CAR T cells | Phase 1 |
| 4D-150 IVT | Phase 3 |
| 5 Azacytidine | Phase 3 |
| 5-flurorouracil | Phase 4 |
| 5-Flurouracil | Phase 4 |
| 5-FU | Phase 4 |
| AAA817 | Phase 3 |
| abatacept | Phase 1 |
| ABBV-155 | Phase 1 |
| ABBV-637 | Phase 1 |
Showing 10 of 511 candidates. Sign up for full pipeline.
Frequently asked questions
How many drug candidates are in Merus N.V.'s pipeline?
Merus N.V. (MRUS) has 511 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Merus N.V.'s lead drug candidate?
Merus N.V.'s most advanced tracked candidate is 19-28z/IL-18 CAR T cells (Phase 1) for Philadelphia-Negative ALL.
What is Merus N.V.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Merus N.V. has approximately 22.6 months of cash runway.
What is Merus N.V.'s market capitalization?
Merus N.V.'s market capitalization is approximately $6.8B.
Who is the CEO of Merus N.V.?
Dr. Jan G.J. van de Winkel Ph.D. is the chief executive officer of Merus N.V. (MRUS).
Get the full picture on Merus N.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.